Equities
Health CarePharmaceuticals and Biotechnology
  • Price (SEK)258.40
  • Today's Change4.20 / 1.65%
  • Shares traded259.79k
  • 1 Year change+0.20%
  • Beta0.1856
Data delayed at least 15 minutes, as of Apr 16 2024 17:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Key statistics

On Tuesday, Swedish Orphan Biovitrum AB (publ) (SOBI:STO) closed at 258.40, -14.44% below its 52-week high of 302.00, set on Feb 01, 2024.
52-week range
Today
189.03Aug 08 2023302.00Feb 01 2024
Short selling activity
Low
Med
High
Provided by S&P Global Market Intelligence
Open251.60
High259.40
Low251.00
Bid--
Offer--
Previous close254.20
Average volume337.40k
Shares outstanding354.36m
Free float195.68m
P/E (TTM)34.97
Market cap90.08bn SEK
EPS (TTM)7.27
SEK
Data delayed at least 15 minutes, as of Apr 16 2024 17:00 BST.
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.
S&P Global Market Intelligence Short Selling Activity © S&P Global Market Intelligence. All rights reserved.
Although S&P Global Market Intelligence has made every effort to ensure this data is correct, nevertheless no guarantee is given to the accuracy or completeness. Any opinions or estimates expressed herein are those of S&P Global Market Intelligence on the date of preparation and are subject to change without notice; however no such opinions or estimates constitute legal, investment or other advice. You must therefore seek independent legal, investment or other appropriate advice from a suitably qualified and/or authorised and regulated advisor prior to making any legal, investment or other decision. This is intended for information purposes only and is not intended as an offer or recommendation to buy, sell or otherwise deal in securities.